Logo Logo

Publications by Naumann, N.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 7.

Journal article

Metzgeroth, G.; Schwaab, J.; Naumann, N.; Haferlach, C.; Jawhar, M.; Horny, H.-P.; Dirk, J.; Kratz-Albers, K.; Krämer, D.; Mayer, S.; Storch, N.; Burchert, A.; Haferlach, T.; Cross, N. C. P.; Hofmann, W.-K.; Fabarius, A.; Reiter, A. (2017): Clinical characteristics and treatment with ruxolitinib in patients with PCM1-JAK2 and BCR-JAK2 positive myeloid/lymphoid neoplasms with eosinophilia. In: Oncology Research and Treatment, Vol. 40: p. 196

Jawhar, M.; Schwaab, J.; Schnittger, S.; Meggendorfer, M.; Pfirrmann, Markus; Sotlar, K.; Horny, H. P.; Metzgeroth, G.; Kluger, S.; Naumann, N.; Haferlach, C.; Haferlach, T.; Valent, P.; Hofmann, W. K.; Fabarius, A.; Cross, N. C.; Reiter, A. (2016): Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. In: Leukemia, Vol. 30, No. 1: pp. 136-143

Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H.-P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C. P.; Fabarius, A.; Hofmann, W.-K.; Valent, P.; Metzgeroth, G.; Reiter, A. (2016): Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. In: Leukemia, Vol. 30, No. 12: pp. 2342-2350

Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H. P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C.; Fabarius, A.; Hofmann, W. K.; Valent, P.; Metzgeroth, G.; Reiter, A. (2016): Splenomegaly and elevated alkaline phosphatase are strong and independent adverse prognostic markers in patients with systemic mastocytosis. In: Haematologica, Vol. 101: p. 559

Jawhar, M.; Schwaab, J.; Meggendorfer, M.; Naumann, N.; Kluger, S.; Horny, H.-P.; Sotlar, K.; Haferlach, T.; Fabarius, A.; Hofmann, W.-K.; Reiter, A.; Metzgeroth, G. (2016): Mast cell leukemia: clinical heterogeneity, molecular aberrations and prognostic factors. In: Oncology Research and Treatment, Vol. 39: p. 24

Naumann, N.; Jawhar, M.; Schwaab, J.; Metzgeroth, G.; Khaled, N.; Horny, H.-P.; Sotlar, K.; Valent, P.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Meggendorfer, M.; Cross, N. C. P.; Hofmann, W. K.; Reiter, A.; Fabarius, A. (2016): Incidence and prognostic impact of cytogenetic aberrations in systemic mastocytosis. In: Oncology Research and Treatment, Vol. 39: p. 25

Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H.-P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C. P.; Fabarius, A.; Hofmann, W.-K.; Valent, P.; Metzgeroth, G.; Reiter, A. (2016): Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. In: Oncology Research and Treatment, Vol. 39: p. 232

This list was generated on Fri Apr 16 01:11:19 2021 CEST.